Cyclin D1 Overexpression With Cytoplasmic Localization Distinguishes Erdheim-Chester Disease From Reactive...

Area of Science:

• Oncology
• Pathology
• Genetics

Background:

• Erdheim-Chester disease (ECD) is a rare histiocytic disorder.
• Distinguishing ECD from inflammatory mimics in biopsies is difficult.
• Molecular confirmation of MAPK pathway mutations is often required for ECD diagnosis.

Purpose of the Study:

• To evaluate cyclin D1 and pERK as immunohistochemical markers for MAPK pathway activation in ECD.
• To compare marker utility in ECD versus its histopathologic mimics.

Main Methods:

• Analysis of 41 clinically confirmed ECD cases and histopathologic mimics.
• Immunohistochemical staining for cyclin D1 and pERK.
• Correlation with known MAPK pathway genetic alterations.

Main Results:

• Cyclin D1 overexpression observed in 90% of ECD cases (37/41).
• pERK expression detected in 82% of ECD cases (32/39).
• Cyclin D1 was largely negative in mimics, except for xanthogranuloma.

Conclusions:

• Cyclin D1 and pERK immunohistochemistry can support ECD diagnosis.
• Strong cyclin D1 expression in histiocytes aids ECD identification.
• These markers are valuable adjuncts in the correct clinical context.